No abstract

protecting immune-compromised patients. In the presence of scarce resources, equitable and effective risk-benefit allocation will be vital, prioritizing vulnerable patients. Timing immunotherapy with vaccination and determining vaccination response will be crucial. Concurrent SARS-CoV-2 infection should not prevent delivery of effective immunomodulatory therapy in patients with severe autoimmune diseases, essential for the protection and recovery of vital organ function.